APhase i study of the SMAC-mimetic birinapant in adults with refractory solid tumorsor lymphoma

Molecular Cancer Therapeutics

Volumn 14, Issue 11, 2015, Pages 2569-2575

  Amaravadi, Ravi K ^a   Schilder, Russell J ^b   Martin, Lainie P ^c   Levin, Myron ^d   Graham, Martin A ^e,g   Weng, David E ^e,h   Adjei, Alex A ^f  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c FOX CHASE CANCER CENTER   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e TetraLogic Pharmaceuticals   (United States)

^f ROSWELL PARK CANCER INSTITUTE   (United States)

^g PKPD Bioscience   (United States)

^h ANNE ARUNDEL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIRINAPANT; DIPEPTIDE; INDOLE DERIVATIVE; INHIBITOR OF APOPTOSIS PROTEIN;

ADULT; AGED; APOPTOSIS; AREA UNDER THE CURVE; CHEMICALLY INDUCED; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; HEADACHE; HUMAN; LYMPHOMA; MALE; METABOLISM; MIDDLE AGED; NAUSEA; NEOPLASMS; PATHOLOGY; PHASE 1 CLINICAL TRIAL; TREATMENT OUTCOME; VERY ELDERLY; VOMITING; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; AREA UNDER CURVE; BLOTTING, WESTERN; DIPEPTIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HEADACHE; HUMANS; INDOLES; INHIBITOR OF APOPTOSIS PROTEINS; LYMPHOMA; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; TREATMENT OUTCOME; VOMITING;

EID: 84958171214     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-15-0475     Document Type: Article

References (30)

1. Hunter AM, LaCasse EC, Korneluk RG. The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis 2007;12:1543-68.
2. LaCasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S, Korneluk RG. IAP-targeted therapies for cancer. Oncogene 2008;27:6252-75.
3. Ebert G, Allison C, Preston S, Cooney J, Toe JG, Stutz MD, et al. Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis. Proc Natl Acad Sci U S A 2015;112:5803-8.
4. Gyrd-Hansen M, Meier P. IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat Rev Cancer 2010;10:561-74.
5. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012;483:603-7.
6. Beug ST, Cheung HH, LaCasse EC, Korneluk RG. Modulation of immune signalling by inhibitors of apoptosis. Trends Immunol 2012;33:535-45.
7. Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 2005;5:876-85.
8. Bertrand MJ, Milutinovic S, Dickson KM, Ho WC, Boudreault A, Durkin J, et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell 2008;30:689-700.
9. Verhagen AM, Ekert PG, Pakusch M, Silke J, Connolly LM, Reid GE, et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000;102:43-53.
10. Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000;102:33-42.
11. Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU, et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 2007;131:682-93.
12. SMC. The discovery and development ofSMACmimetics-small molecule antagonists of the inhibitor of apoptosis proteins. In:Macor JA, editor. Annual reports in medicinal chemistry 2011. Chapter 13. Washington, DC: American Chemistry Society; 2011.
13. Gaither A, Porter D, Yao Y, Borawski J, Yang G, Donovan J, et al. A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor-alpha signaling. Cancer Res 2007;67:11493-8.
14. Varfolomeev E, Blankenship JW,Wayson SM, Fedorova AV, Kayagaki N,Garg P, et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 2007;131:669-81.
15. Condon SM, Mitsuuchi Y, Deng Y, LaPorte MG, Rippin SR, Haimowitz T, et al. Birinapant, a smac-mimetic with improved tolerability for the treatment of solid tumors and hematological malignancies. J Med Chem 2014;57:3666-77.
16. Fulda S. Smac mimetics as IAP antagonists. Semin Cell Dev Biol 2015;39:132-8.
17. Bai L, Smith DC, Wang S. Small-molecule SMAC mimetics as new cancer therapeutics. Pharmacol Ther. 2014;144:82-95.
18. Benetatos CA, Mitsuuchi Y, Burns JM, Neiman EM, Condon SM, Yu G, et al. Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-kappaB activation, and is active in patient-derived xenograft models. Mol Cancer Ther 2014; 13:867-79.
19. Carter BZ, Mak PY, Mak DH, Shi Y,Qiu Y, Bogenberger JM, et al. Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents. J Natl Cancer Inst 2014;106:djt440.
20. Carter BZ, Mak DH, Schober WD, Koller E, Pinilla C, Vassilev LT, et al. Simultaneous activation of p53 and inhibition of XIAP enhance the activation of apoptosis signaling pathways in AML. Blood 2010;115: 306-14.
21. Krepler C, Chunduru SK, Halloran MB, He X, Xiao M, Vultur A, et al. The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells. Clin Cancer Res 2013;19:1784-94.
22. Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC. Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 1997;89:1138-47.
23. Wong H, Budha NR, West K, Blackwood E, Ware JA, Yu R, et al. Dogs are more sensitive to antagonists of inhibitor of apoptosis proteins than rats and humans: a translational toxicokinetic/toxicodynamic analysis. Toxicol Sci 2012;130:205-13.
24. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
25. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-86.
26. Bonate PL. Pharmacokinetic-pharmacodynamic modeling and simulation. 2nd ed. New York/Dordrecht/Heidelberg/London: Springer; 2011. p. 157-86.
27. LevinMJ, Cai GY, Manchak MD, Pizer LI. Varicella-zoster virusDNAin cells isolated from human trigeminal ganglia. J Virol 2003;77:6979-87.
28. Levin MJ, Oxman MN, Zhang JH, Johnson GR, Stanley H, Hayward AR, et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis 2008;197:825-35.
29. Wong WW, Vince JE, Lalaoui N, Lawlor KE, Chau D, Bankovacki A, et al. cIAPs and XIAP regulate myelopoiesis through cytokine production in an RIPK1-and RIPK3-dependent manner. Blood 2014;123:2562-72.
30. Moulin M, Anderton H, Voss AK, Thomas T,WongWW,Bankovacki A, et al. IAPs limit activation of RIP kinases by TNF receptor 1 during development. EMBO J 2012;31:1679-91.